May 30, 2026 - ChartAlert®

ASIANPAINT – Asian Paints – Q4 FY26 Financial Results – 29-May-26

Asian Paints’ FY26 delivered margin recovery and record FCF despite just 5% topline growth. Q4 re‑acceleration is positive, but re‑rating hinges on H1FY27 volume growth >8–10% as Birla Opus disruption stabilises. Home décor losses narrowing and international profitability doubling are tailwinds; monitor Q1 volumes and receivables.

1–2 minutes

🔍 Observations

Topline

Revenue from operations grew 5.0% YoY (₹33,906 Cr → ₹35,584 Cr FY26); Q4 alone surged 10.6% YoY, signalling Q4 acceleration after a sluggish first half.
Decorative paints India (~84% of consolidated revenue) remains the primary driver; international business (+8.9% YoY to ₹3,340 Cr) added meaningful incremental contribution.
Other income jumped 26.4% YoY (₹573 Cr → ₹724 Cr), partly cushioning operating pressure — a non-trivial ₹724 Cr on a ₹35,584 Cr revenue base.

Bottomline

Reported PAT rose 18.4% YoY (₹3,710 Cr → ₹4,395 Cr FY26); Q4 PAT up 69.3% YoY (₹701 Cr → ₹1,185 Cr), aided by the base effect of ₹183 Cr exceptional items in Q4FY25.
Exceptional items (₹158 Cr in FY26 vs. ₹365 Cr in FY25) largely impairments on international/home décor subsidiaries — lower drag this year inflates apparent YoY PAT improvement.
Effective tax rate held steady at ~26.8% (FY26: ₹1,609 Cr on PBT ₹6,003 Cr vs. ~27.3% in FY25).

Margins

PBDIT margin expanded ~110 bps YoY (17.8% → 18.9% on net sales); raw material cost ratio improved — materials consumed fell from ₹15,794 Cr to ₹15,384 Cr despite ~5% revenue growth, implying meaningful gross margin recovery.
Net profit margin (PAT/Revenue from ops): 12.4% FY26 vs. 10.9% FY25 — a clean 150 bps expansion, driven by operating leverage and lower input costs.
Employee costs (+7.8% YoY) and other expenses (+5.2% YoY) grew broadly in line with revenue — cost discipline holding.

Growth Trajectory

FY26 topline growth (5.0%) is the slowest in several years — volume-led growth story partially stalled amid competitive intensity from Birla Opus and muted urban demand.
Q4 re-acceleration (+10.6% revenue, +24.4% PBDIT) is encouraging but must sustain through H1FY27 to confirm a structural recovery rather than base-effect rebound.
Home décor (Kitchen + Bath) remains loss-making at PBIT level (combined ~₹19 Cr loss in FY26 vs. ~₹51 Cr in FY25) — improvement trajectory present but dilutive to consolidated ROCE.

GLENMARK – Glenmark Pharmaceuticals – Q4 FY26 Financial Results – 29-May-26

Glenmark’s FY26 marks inflection — debt‑free, doubled pre‑exceptional profitability, and robust OCF. Risks: +48.5% receivables surge and ₹22,661M exceptional charges cloud earnings quality. If receivables normalize and charges stabilize, ~₹20,873M FCF supports re‑rating; monitor DSO trends, exceptional disclosures, and ₹15,361M non‑current liability build.

1–2 minutes

🔍 Observations

Topline

Net sales surged 27.1% YoY (₹131,458M → ₹167,114M), driven by broad-based geographic expansion and the Ichnos Sciences consolidation effect post-demerger.
Q4FY26 net sales of ₹37,603M grew 16.8% YoY vs Q4FY25’s ₹32,201M, though sequentially softer vs Q3FY26’s ₹38,880M — slight volume moderation at year-end.
Other operating income jumped to ₹2,711M in FY26 vs ₹1,759M in FY25, reflecting licensing/milestone receipts boosting reported revenue quality.

Bottomline

Reported PAT: ₹13,620M in FY26 vs ₹10,471M in FY25 (+30.1% YoY), but exceptional losses of ₹22,661M (vs ₹3,728M prior year) dominate the narrative — pre-exceptional PBT was ₹42,508M vs ₹17,720M (+139.9% YoY), a far stronger underlying picture.
Q4FY26 PAT of ₹3,013M was inflated by negative current tax (refund of ₹301M) — normalized earnings were lower; Q3FY26 PAT of ₹4,032M was cleaner.
Basic EPS: ₹48.26 in FY26 vs ₹37.11 in FY25 — EPS growth understates operational improvement given the drag from escalating exceptional charges.

Margins

EBITDA proxy (pre-exceptional PBT + Finance costs + D&A): ₹42,508M + ₹2,087M + ₹5,735M = ₹50,330M on revenue of ₹169,825M → EBITDA margin ~29.6% in FY26 vs (₹17,720M + ₹2,071M + ₹4,860M) = ₹24,651M on ₹133,217M → 18.5% in FY25. A 1,110 bps margin expansion.
Reported net margin: ₹13,620M / ₹169,825M = 8.0% — depressed by exceptional items; pre-exceptional PBT margin = 25.0%.
Cost of materials + stock-in-trade consumed ₹47,475M (net of inventory changes ₹6,106M) = ₹41,369M effective material cost on ₹167,114M net sales = 24.8% — improved from prior year’s effective ~32.7%.

Growth Trajectory

Revenue CAGR implied (FY25→FY26): +27.1% — sustainable pace uncertain; Ichnos consolidation is a one-time step-up in the base.
Employee costs grew 18.4% YoY (₹30,221M → ₹35,779M) — below revenue growth, indicating early operating leverage.
Other expenses grew 13.6% YoY (₹35,950M → ₹40,848M) — again below revenue growth, reinforcing operating leverage thesis.

BEML – Beml Ltd – Q4 FY26 Financial Results – 29-May-26

BEML’s FY26 shows earnings compression — PAT down >50% on margin erosion, doubled provisions, and ballooning receivables despite revenue growth. CWIP tripling and Metro/Defence/Railways pipeline support thesis, but re‑rating hinges on expense normalization, receivables conversion, and provision reversal. Until OCF/FCF turn positive, execution visibility drives valuation.

1–2 minutes

🔍 Observations

Topline

FY26 revenue grew 8.2% YoY (₹4,02,222L → ₹4,35,053L), modest but consistent; Q4FY26 at ₹1,79,417L surged 8.6% over Q4FY25, confirming H2-heavy execution pattern
Q3FY26 revenue of ₹1,08,327L was unusually weak — sequential collapse of ~40% — pointing to lumpy government order-driven recognition
Other income rose 24% YoY (₹2,373L → ₹2,944L), marginal contributor but directionally positive

Bottomline

FY26 PAT collapsed 51.7% YoY (₹29,252L → ₹14,136L) despite 8.2% revenue growth — a sharp earnings-quality deterioration
Q3FY26 posted a PAT loss of ₹2,238L; Q4FY26 recovered to ₹17,982L, but Q4FY25 PAT was ₹28,755L — Q4 profitability down 37.5% YoY
Effective tax rate distorted by large deferred tax credit of ₹6,965L in FY26 vs. ₹1,161L charge in FY25; underlying cash tax burden (₹12,725L) stayed elevated

Margins

FY26 EBITDA (PBT + Finance Costs + D&A): ₹19,956 + ₹4,539 + ₹8,348 = ₹32,843L on revenue of ₹4,35,053L → EBITDA margin ~7.5%, down from ~13.1% in FY25 (₹40,376 + ₹5,431 + ₹7,134 = ₹52,941L on ₹4,02,222L)
Net margin compressed to 3.2% (₹14,136L / ₹4,35,053L) vs. 7.3% in FY25 — a 410bps contraction
Other expenses surged 38.8% YoY (₹67,558L → ₹93,787L) on only 8.2% revenue growth — the single largest margin erosion driver

Growth Trajectory

Revenue CAGR is low-single-digit; at current trajectory BEML is not a high-growth compounder but an order-execution vehicle dependent on government capex cycles
Provisions rose sharply: current provisions jumped from ₹25,870L to ₹53,259L (+105.9%), signalling warranty, contractual, or contingent liability build-up
Non-current liabilities grew 8.4% (₹1,11,816L → ₹1,21,178L) while equity grew just 1.6% — leverage creeping up structurally

MAXHEALTH – Max Healthcare Institute – Q4 FY26 Earnings Call – 22-May-26

Max Healthcare’s topline growth hinges on non-onco scaling and greenfield execution, while margins face structural pressure from oncology mix shifts and ALOS volatility.

1–2 minutes

Also see: MAXHEALTH – Max Healthcare Institute – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Oncology share stabilizes at 21–22% + Gurgaon breakeven in FY28.
Revenue grows 12–15% CAGR (ex-oncology: 15–18%) as digital/international offset oncology drag. EBITDA margins hover at 26–27% due to ALOS/labor cost lags. Free cash flow ~₹1,500 crore/year funds ₹1,200–1,500 crore annual capex, keeping net debt-to-EBITDA <1.2x.

SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Earnings Call – 22-May-26

Sun Pharmaceutical Industries’ topline growth hinges on Innovative Medicines and Organon synergies, while margins and EPS are sensitive to cost normalization, tax rates, and execution risks.

1–2 minutes

Also see: SUNPHARMA – Sun Pharmaceutical Industries – Q4 FY26 Financial Results – 22-May-26

3-Scenario Framework

📊 Base Case (50% Probability)

Key Variables: Organon integration on track (Q4 FY27), Innovative Medicines growth (15–20% YoY), margin stabilization (27–28% EBITDA).
Outcome: High single-digit topline growth achieved, EPS stable with tax rate at 25%, generics recovery lagging but offset by Innovative Medicines. Semaglutide gains traction in H2 FY27.

PAGEIND – Page Industries – Q4 FY26 Earnings Call – 21-May-26

Page Industries’ topline growth hinges on volume momentum and premiumization, while margins face structural pressure from input costs and marketing spend, with EBITDA likely normalizing to 19–21%.

1–2 minutes

Also see: PAGEIND – Page Industries – Q4 FY26 Financial Results – 21-May-26

3-Scenario Framework

📊 Base Case (60% Probability)

Key Variables: Stable macro, moderate input inflation, sustained premiumization.
Revenue grows 10–12% YoY (volume-led), with EBITDA margins at 20–21% (marketing spend ~5%, partial cost pass-through). E-commerce share rises to 16–17%, offsetting offline softness. Subsidies (INR 40–50 crore) support cash flow. Implication: *Topline resilience, margin stability, but limited upside.